Tyr424
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr424  -  TGFBR2 (human)

Site Information
GQVGTARyMAPEVLE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2869602

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 11 ) , immunoprecipitation ( 11 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , mutation of modification site ( 12 ) , phospho-antibody ( 1 , 11 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , breast adenocarcinoma ( 1 ) , breast cancer, triple negative ( 1 ) , gastric cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , gastric carcinoma ( 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
MURF1 (human) ( 1 )
Kinases, in vitro:
TGFBR2 (human) ( 12 )

Downstream Regulation
Effects of modification on TGFBR2:
enzymatic activity, induced ( 12 )
Effects of modification on biological processes:
transcription, altered ( 12 )

References 

1

Sami E, Paul BT, Koziol JA, ElShamy WM (2020) The immunosuppressive microenvironment in BRCA1-IRIS-overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages. Cancer Res
31911557   Curated Info

2

Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

3

Mulhern D (2012) CST Curation Set: 14193; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

4

Zhou J (2012) CST Curation Set: 14105; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

5

Zhou J (2012) CST Curation Set: 14007; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

6

Zhou J (2012) CST Curation Set: 14008; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

7

Zhou J (2012) CST Curation Set: 14009; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

8

Zhou J (2012) CST Curation Set: 14010; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

9

Zhou J (2012) CST Curation Set: 13840; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

10

Rikova K (2012) CST Curation Set: 13730; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

11

Chiang TA, et al. (2010) Hyperosmolarity enhanced susceptibility to renal tubular fibrosis by modulating catabolism of type I transforming growth factor-beta receptors. J Cell Biochem 109, 663-71
20091742   Curated Info

12

Lawler S, et al. (1997) The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 272, 14850-9
9169454   Curated Info